Hepatitis C: controversies, strategies and challenges

Area of Science:

• Virology
• Hepatology
• Epidemiology

Background:

• Hepatitis C virus (HCV) is a single-stranded RNA virus with multiple genotypes and subtypes.
• Risk factors for HCV include IV drug use (42%), blood transfusions (6%), and other exposures, with 40% having no identifiable risk.
• HCV quasispecies complexity correlates with disease duration, viremia, genotype 1, and poor interferon response.

Purpose of the Study:

• To outline the epidemiology, diagnosis, and treatment of Hepatitis C virus infection.
• To discuss the impact of HCV genotypes and quasispecies on disease progression and treatment outcomes.
• To evaluate the efficacy of standard and combination therapies for chronic HCV infection.

Main Methods:

• Diagnosis involves anti-HCV enzyme immunoassay (EIA) with confirmation by recombinant immunoblot assay (RIBA) or HCV RNA detection via polymerase chain reaction (PCR).
• Standard therapy utilized interferon alfa-2b (Intron A) for 6 months.
• Treatment efficacy was assessed by complete response (normal aminotransferases, undetectable HCV RNA) and relapse rates.

Main Results:

• Standard interferon therapy yields a 40-50% response rate, with 60-80% relapse within six months.
• Longer treatment durations (12-18 months) and patient selection (low HCV RNA, no cirrhosis) may improve outcomes.
• Combination therapy with ribavirin has shown dramatically reduced relapse rates.

Conclusions:

• Chronic Hepatitis C virus infection requires careful diagnosis and management.
• Optimizing treatment duration, patient selection, and combination therapies are crucial for improving sustained virologic response.
• Combination therapy, particularly with ribavirin, offers a significant improvement in reducing relapse rates for chronic HCV.